Global X China Biotech Innovation ETF
Limited financial coverage for CHB.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
This fund commits at least 80% of its overall assets, alongside any borrowed capital used for investment, to the securities tracked by its benchmark index. This also includes American and Global Depositary Receipts that are derived from those same index securities. The underlying index itself is specifically designed to provide investors with exposure to exchange-listed companies operating directly within China's biotechnology sector.
- IPO
- 2020
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on CHB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.39M
- Div Yield
- 0.59%
- 52W High
- $9.76
- 52W Low
- $6.63
- 50D MA
- $7.26
- 200D MA
- $7.66
- Beta
- 0.66
- RSI (14)
- 30
- Avg Volume
- 712
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Champion reported a steep revenue decline and a large net loss in a weak housing market, while emphasizing cost cuts, liquidity preservation, and selective optimism around stimulus-driven recovery potential.· February 19, 2009
- Q4 revenue fell 42% year over year to $187.9 million; full-year revenue declined 19% to $1.03 billion.
- Q4 net loss was $20.8 million, or $0.27 per diluted share; full-year net loss was just under $200 million, or $2.57 per diluted share.
- Manufacturing volumes and backlog were very weak: U.S. shipments fell to 1,951 units, and year-end manufacturing backlog was only $7 million.
- Management cut costs aggressively, idled plants, and said annualized fixed-cost reductions exceeded $30 million.
- Liquidity and covenant compliance remained intact at year-end, but management warned 2009 would stay challenging, especially in the first half.
Champion reported fourth-quarter 2008 consolidated revenue of $187.9 million, down 42% from $325.6 million a year earlier. The company posted a pretax loss of $26.6 million versus pretax income of $11.2 million last year, and net loss of $20.8 million, or $0.27 per diluted share, versus a loss of $6 million, or $0.08 per diluted share. Full-year revenue declined 19% to $1.03 billion, pretax loss was $52 million versus pretax income of $4 million, and net loss was just under $200 million, or $2.57 per diluted share. Management did not provide formal next-quarter or full-year guidance, but said industry volumes are likely to fall again in 2009, especially in the first half; the UK margin outlook for 2009 was said to be about 5% to 6%, down from a normal 8% to 8.5%. Reported items included non-cash foreign currency transaction losses of $8.7 million, a $6.3 million retail inventory write-down, $1.2 million of restructuring charges, and a $600,000 loss on debt retirement. Cash used in operations was $3.4 million in Q4, and year-end cash, cash equivalents, and short-term investments were $52.8 million, with $65.6 million of total liquidity including revolver availability. Total debt was about $313 million at year-end, and management said the company remained in compliance with debt covenants.
Bill Griffiths framed the quarter as the result of a severe global financial crisis and historically weak housing demand, with financing availability still a major constraint. He stressed cost reduction, liquidity preservation, and capacity management as the main priorities, noting that the company has closed or idled multiple plants and reduced headcount by 42%. He also said the company is using the slowdown to refresh products toward smaller, more affordable, more energy-efficient homes and to target adjacent markets such as multi-family, hotels, seniors, and student housing.
Phyllis Knight focused on the earnings impact of weak demand, currency pressure, and several special items. She cited Q4 revenue of $187.9 million, a pretax loss of $26.6 million, net loss of $20.8 million, and special items including $8.7 million of foreign currency losses and a $6.3 million retail inventory charge; for the full year she highlighted $1.03 billion of revenue, a $52 million pretax loss, and a net loss of just under $200 million, including a $165 million non-cash tax charge to establish a valuation allowance. On liquidity, she said the company used $3.4 million in operations in Q4, ended with $52.8 million of cash and $65.6 million of total liquidity, and remained in compliance with debt covenants with over $10 million of cushion at year-end.
Analysts focused on retail floor-plan financing, covenant headroom, UK margin pressure, Canadian demand, and the NYSE listing issue. Management said exposure to national floor-plan lenders had historically been a little over 40% of North American revenue, with GE the largest relationship and Textron historically in the low-to-mid teens, while they encouraged dealers toward local banks and said they were not ready to announce any companywide financing program. On covenants, Phyllis Knight said there had been no change, the company expected to stay compliant through 2009, and the April lender update was only a reporting requirement, not a new covenant test. On the listing, Bill Griffiths said Champion had submitted its plan to the NYSE and was considering all options, including but not limited to a reverse split.
Management said the company exited 2008 with covenant compliance, $65.6 million of total liquidity, and a stronger cost base after major plant closures and headcount reductions. They also pointed to possible support from the stimulus package, the $8,000 first-time homebuyer tax credit, and future foreclosure-mitigation efforts as potential tailwinds, even if the impact would likely be delayed. In the UK, Bill Griffiths said the business is normally an 8% to 8.5% margin business and could recover toward that level in 2010 or 2011.
The call was dominated by falling demand, weak credit availability, and severe backlog compression, especially in U.S. manufacturing and UK orders. Management repeatedly warned that 2009 would be difficult, likely worse in the first half, with volumes still expected to decline and margins under pressure. The company also faced ongoing risks from retail inventory weakness, floor-plan financing disruption, and uncertainty around its NYSE listing and possible reverse split.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 0.0%
- Shares Outstanding
- 209.51K
- Float Shares
- 0
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 6, 09 | LYNCH GEORGE M | other | 7,000 |
| May 6, 09 | MADDEN THOMAS A | other | 8,050 |
| May 6, 09 | ANESTIS ROBERT W | other | 7,000 |
| Mar 6, 09 | SCHOLTEN ROGER K | other | 85,000 |
| Mar 6, 09 | GRIFFITHS WILLIAM C | other | 200,000 |
| Mar 6, 09 | MADDEN THOMAS A | buy | 50,000 |
| Feb 24, 09 | ANESTIS ROBERT W | buy | 37,000 |
| Feb 24, 09 | ANESTIS ROBERT W | buy | 35,000 |
| Feb 20, 09 | GRIFFITHS WILLIAM C | other | 30,228 |
| Feb 18, 09 | GRIFFITHS WILLIAM C | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CHB coverage
Recent articles, reports, and earnings notes.
No research on CHB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHB report →Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
gurufocus.com · May 28
Challenger Assays Extend New Open Pittable Mineralisation
accessnewswire.com · May 19
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
globenewswire.com · May 12
Challenger West Assays Return Grades up to 60g/t Au
accessnewswire.com · Apr 21
First Challenger Assays Return Grades up to 170g/t Au
accessnewswire.com · Apr 19
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
globenewswire.com · Mar 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.